Valuation: Celldex Therapeutics, Inc.

Market Cap 215.37Cr 196.16Cr 180.75Cr 164.42Cr 308.45Cr 20TCr 324.18Cr 2.2TCr 874.34Cr 11TCr 808.07Cr 791.03Cr 34TCr P/E 2026 *
-6.66x
P/E 2027 * -6.81x
Enterprise Value 156.06Cr 142.14Cr 130.98Cr 119.14Cr 223.51Cr 14TCr 234.91Cr 1.59TCr 633.58Cr 7.89TCr 585.55Cr 573.21Cr 25TCr EV / Sales 2026 *
1,127x
EV / Sales 2027 * 211x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celldex Therapeutics, Inc.

Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 30/07/2014
Chief Executive Officer 64 01/09/2008
Director of Finance/CFO 55 01/04/2009
Director TitleAgeSince
Director/Board Member 64 01/12/2008
Chairman 80 05/06/2025
Director/Board Member 93 01/03/2008
Change 5-day change 1-year change 3-year change Capi.($)
+10.82%+992.89% - - 215.37Cr
-2.49%-3.76%+50.31%+62.10% 6.37TCr
-0.63%-2.91%+6.20%+89.22% 5.86TCr
-2.37%-2.22%+22.87%+82.31% 5.42TCr
-2.19%-6.15%+11.92%+108.08% 4.47TCr
-1.89%-7.28%+13.22%+19.74% 4.05TCr
-0.93%-0.47%+19.73%+43.75% 3.63TCr
+1.11%-6.44%+130.68%+641.83% 3.49TCr
-0.80%+0.61%+77.26%+56.26% 3.23TCr
-2.17%+16.65%-29.21%+474.05% 3.1TCr
Average -0.15%-1.22%+33.67%+175.26% 4TCr
Weighted average by Cap. -1.41%-1.85%+32.16%+150.90%

Financials

2026 *2027 *
Net sales 13.85L 12.61L 11.62L 10.57L 19.83L 13Cr 20.84L 1.41Cr 56.21L 7Cr 51.95L 50.85L 22Cr 70.72L 64.42L 59.36L 53.99L 1.01Cr 65Cr 1.06Cr 7.22Cr 2.87Cr 36Cr 2.65Cr 2.6Cr 112.26Cr
Net income -31Cr -28Cr -26Cr -24Cr -44Cr -2.86TCr -46Cr -315.37Cr -125.34Cr -1.56TCr -115.84Cr -113.4Cr -4.9TCr -34Cr -31Cr -28Cr -26Cr -48Cr -3.11TCr -51Cr -343.15Cr -136.38Cr -1.7TCr -126.05Cr -123.39Cr -5.33TCr
Net Debt -59Cr -54Cr -50Cr -45Cr -85Cr -5.49TCr -89Cr -605.77Cr -240.76Cr -3TCr -222.52Cr -217.82Cr -9.41TCr -66Cr -60Cr -55Cr -50Cr -95Cr -6.11TCr -99Cr -674.43Cr -268.05Cr -3.34TCr -247.74Cr -242.51Cr -10TCr
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Celldex Therapeutics, Inc.